Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_assertion type Assertion NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_head.
- NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_assertion description "[Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_provenance.
- NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_assertion evidence source_evidence_literature NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_provenance.
- NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_assertion SIO_000772 19361262 NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_provenance.
- NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_assertion wasDerivedFrom befree-20140225 NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_provenance.
- NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_assertion wasGeneratedBy ECO_0000203 NP316649.RAchkU-mijuVcXcMWJdzTMUxOl8s7xNOS6CPzf6rPopp4130_provenance.